IgGenix, Inc., a preclinical antibody discovery and development company taking a revolutionary approach to address IgE-mediated diseases, presented data on the company's lead candidate, IGNX001, an IgG4 monoclonal antibody-based therapeutic candidate for peanut allergy. The company also presented data in Atopic Dermatitis (AD), showcasing the widespread utility of its proprietary SEQ SIFTER™ antibody discovery platform in IgE-mediated disease beyond allergies. These data were presented during th
Pensioners are being hit with tax bills of nearly £100,000 as a result of taking their pension in cash, analysis revealed.
Calgary, Alberta--(Newsfile Corp. - June 3, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) (FSE: 2VF0) is pleased to announce it has signed a Letter of Intent ("LOI") with CytoImmune Therapuetics ("CytoImmune") to re-establish production of ACP-01 ("ACP") in CytoImmune's state-of-the-art clinical cell manufacturing facility. The Company is also pleased to announce that it has received commitments for $1,800,000 of Units in a non-brokered private placement as more fully described below.Cyt
Simbolo | Ultimo prezzo | Variazione | % variazione |
---|---|---|---|
Simbolo | Ultimo prezzo | Variazione | % variazione |
---|---|---|---|
Simbolo | Ultimo prezzo | Variazione | % variazione |
---|---|---|---|
Simbolo | Ultimo prezzo | Variazione | % variazione |
---|---|---|---|
Simbolo | Ultimo prezzo | Variazione | % variazione |
---|---|---|---|
Simbolo | Ultimo prezzo | Variazione | % variazione |
---|---|---|---|
Simbolo | Ultimo prezzo | Variazione | % variazione |
---|---|---|---|
Simbolo | Ultimo prezzo | Variazione | % variazione |
---|---|---|---|